CD274 and non-small cell lung carcinoma: Pembrolizumab was approved in 2016 by the Food and Drug Administration (FDA) as first-line monotherapy in treatment‐naive metastatic NSCLC with a PD‐L1 tumor proportion score (TPS) ≥ 50% (4).